E1018 + Placebo

Phase 1Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malaria

Conditions

Malaria, Healthy Participants

Trial Timeline

Feb 26, 2025 → Dec 23, 2025

NCT ID

NCT06854042

About E1018 + Placebo

E1018 + Placebo is a phase 1 stage product being developed by Eisai for Malaria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06854042. Target conditions include Malaria, Healthy Participants.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06854042	Phase 1	Recruiting	Feb 26, 2025	Dec 23, 2025	Malaria

Competing Products

20 competing products in Malaria

See all competitors

Product	Company	Stage	Hype Score
SAR97276A	Sanofi	Phase 2	51
SJ733 + Cobicistat	Eisai	Phase 1	33
(+)-SJ000557733 (SJ733)	Eisai	Phase 2	52
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	33
ZY19489 Capsule + Placebo Capsule	Zydus Lifesciences	Phase 1	33
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mg	Merck	Phase 2	52
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil	Merck	Phase 1	33
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg	Merck	Phase 2	52
KLU156 + Coartem	Novartis	Phase 3	77
KAF156	Novartis	Phase 2	52
KAE609 + IV Artesunate + Coartem	Novartis	Phase 2	52
KAE609	Novartis	Phase 2	52
artemether:lumefantrine (2.5 mg:30 mg)	Novartis	Phase 2/3	65
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	65
INE963	Novartis	Phase 2	52
Ganaplacide + Itraconazole	Novartis	Phase 1	33
KAE609 + Piperaquine Phosphate	Novartis	Phase 1	33
Artemether-lumefantrine	Novartis	Phase 3	77
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	52
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation	Novartis	Phase 2	52

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved